Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters

JRP and VJM are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The authors report no other conflict of interest. Since the start of the COVID-19 pandemic, Severe Acute Respiratory Syndrome Corona...

Full description

Saved in:
Bibliographic Details
Published inPLOS Pathogens Vol. 18; no. 12; p. e1010970
Main Authors Boon, Adrianus C. M., Darling, Tamarand L., Halfmann, Peter J., Franks, John, Webby, Richard J., Barouch, Dan H., Port, Julia R., Munster, Vincent J., Diamond, Michael S., Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Public Library of Science (PLoS) 02.12.2022
Public Library of Science
Subjects
Airborne infection
Allergies
Animal experimentation
Animal models in research
Animals
Biology (General)
Biology and Life Sciences
Conflicts of interest
Coronaviruses
COVID-19
Cricetinae
Disease transmission
Funding
Hamsters
Immunologic diseases. Allergy
Infectious diseases
Influenza
Intermediates
Laboratories
Medical research
Medicine and health sciences
Medicine, Experimental
Mesocricetus
Methods
Mutation
Opinion
Pandemics
Physiological aspects
Proteins
QH301-705.5
R&D
RC581-607
Research & development
Research and Analysis Methods
Respiratory Aerosols and Droplets
SARS-CoV-2
Seroconversion
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccines
Viral diseases
Viruses
United States
Japan
Online AccessGet full text

Cover

More Information
Summary:JRP and VJM are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The authors report no other conflict of interest. Since the start of the COVID-19 pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections worldwide with more than 6.5 million confirmed deaths. Transmission of SARS-CoV-2 can be established by detection of viral RNA, RNA replication intermediates, viable infectious virus, or seroconversion, with the latter two metrics being the most stringent. Since January 2021, the National Institutes of Health SARS-CoV-2 Assessment of Variant Evolution (SAVE) initiative has evaluated the transmission potential of SARS-CoV-2 variants in Syrian hamsters [16]. [...]it is possible that the changes in the spike protein of Omicron affect and reduce stability of the virus in the infected hosts.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Commentary-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
I have read the journal’s policy and the authors of this manuscript have the following competing interests: D.H.B is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The Boon laboratory has received unrelated funding support in sponsored research agreements from AI Therapeutics, GreenLight Biosciences Inc., and Nano targeting & Therapy Biopharma Inc. The Boon laboratory has received funding support from AbbVie Inc., for the commercial development of SARS-CoV-2 mAb. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival Corporation, on the Scientific Advisory Boards of Moderna and Immunome, and has licensed mucosal vaccine technology to Bharat Biotech and Ocugen. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Kaleido, and Emergent BioSolutions and past support from Moderna not related to these studies. The authors report no other conflict of interest.
ISSN:1553-7374
1553-7366
1553-7374
DOI:10.1371/journal.ppat.1010970